Candida albicans is known for its ability to form biofilmscommunities of 22 microorganisms embedded in an extracellular matrix developing on different 23 surfaces. Biofilms are highly tolerant to antifungal therapy. This phenomenon has 24 been partially explained by the appearance of so-called persister cells, phenotypic 25 variants of wild-type cells, capable of surviving very high concentrations of 26 antimicrobial agents. Persister cells in C. albicans were found exceptionally in 27 biofilms while none were detected in planktonic cultures of this fungus. Yet, this topic 28 remains controversial as others could not observe persister cells in biofilms formed 29 by the C. albicans SC5314 laboratory strain. Due to ambiguous data in the literature, 30
INTRODUCTION 41
The yeast Candida albicans is a commensal of humans but also one of the most 42 prevalent fungal pathogens, responsible for superficial infections as well as life-43 threatening systemic infections (1). C. albicans is recognized for its ability to form 44 biofilms that are most frequently associated with nosocomial infections, particularly in 45 immunocompromised patients. 46 composed of different cell types embedded in an extracellular matrix (2) (3) (4) . They biofilm growth as described in (8) and (13) . or increasing the volume of antifungal to 115 fill the well up to the top (350 µL or 3 mL for 96-and 24-well plates, respectively). 116
Clinical isolates were first treated with 64 µg/mL AMB solution. Strains giving rise to 117 colonies were then tested 5 times with 100 µg/mL AMB. 118
Plating 119
Upon 24 hours of antifungal treatment, AMB solution was aspirated and biofilms were 120 washed twice with 1X PBS prior to plating on YPD-agar plates. Biofilms were 121 resuspended in 1x PBS/0.05% Tween-20. For the AMB-treated samples, the whole 122 biofilms were plated. For control biofilms, serial dilutions were performed to allow 123 CFU counting. CFU were counted after incubating the plates at 30 o C for 48 h. 124
125

RESULTS AND DISCUSSION 126
In this work, we aimed to study the occurrence of persister cells in C. albicans 127 biofilms. We applied the protocol published by LaFleur and colleagues, growing the 128 biofilms in RPMI and in a 96-well plate format (8). We set up the protocol with 3 numbers obtained were highly variable for all samples, making any further analysis 138 and comparison impossible (data not shown). 139
We decided to test alternative approaches to circumvent the stickiness of biofilms. 140
Resuspending cells in 20% glycerol/1X PBS for plating helped reducing stickiness, 141 but did not improve consistency (data not shown). We hypothesized that EDTA might 142 reduce adherence of biofilms by binding bivalent cations that are required for the 143 activity of cell surface adhesins (23). Thus, we attempted applying 20% glycerol with 144 a range of EDTA concentrations (0, 50, 100 mM) for plating. 100 µL of EDTA 145 solutions of different concentrations were added to biofilms and left for 10 minutes at 146 room temperature prior to biofilm disruption by scraping and vortexing. None of the 147 applied EDTA solutions allowed abolishing stickiness. Additionally, colonies growing 148 on YPD-agar exhibited a wrinkled morphology, most probably linked to the toxicity of 149 ED TA (24). Finally, we tried adding Tween-20 (0.05%) to PBS. Tween-20 eradicated 150 the problems of stickiness and poor disruption and improved recovery of cells from 151 the biofilms (Fig. 1) . The effect on cell viability was tested using a planktonic culture 152 of SC5314 that was washed and plated on YPD-agar using PBS and PBS-Tween-20 153 solutions. No impact on viability was observed (data not shown). Thus, in the 154 experiments described below, biofilms were resuspended in a 0.05% Tween-20/1X 155 PBS solution. 156
However, even after this modification, the ratio of cells that survived AMB treatment 157 was still inconsistent between repeats. According to Lafleur and colleagues the ratios 158 of C. albicans persister cells in biofilms vary from 0.1% to 2% for different strains, 159 notably from 0.05 to 0.1% for strain CAI4a derivative of C. albicans SC5314 (8). 160
Our values hardly ever exceeded 0.01% persisters per biofilm, even after improving increasing the surface of a biofilm and changing the growth media could improve 163 persister yields and decided to test the protocol described in (13), applying the 164 modifications that were mentioned previously. However, the problem of inconsistency 165 and low ratios of persisters remained (Fig. 2) . 166
In all protocols described previously, the volumes of the media and solutions used for 167 biofilm growth, washing, and AMB treatment were identical. Upon a careful 168 observation, we noticed that C. albicans cells form a dense rim at the border of the 169 air and liquid phases, as a result of agitation during growth. Treating a biofilm with the 170 exact same volume of antifungal and growth medium in static conditions thus could 171 result in cells from the rim escaping treatment. We decided to increase the volume of 172 the applied antifungal solution (filling wells to the top) and, to our surprise, this 173 change in the protocol led to a complete eradication of persisters for the laboratory 174 strain SC5314 and its derivatives. Reproducibly, we did not get any persisters after 175 applying this change for all strains for both RPMI-and GHAUM-grown biofilms. Thus, 176 the volume of the antifungal applied in the original protocols for persister isolation 177 was skewing the results. Increasing the volume of antifungal eliminated this bias, 178 resulting in a complete eradication of any survivors after the antifungal treatment. 179
In our work we used a modified protocol for persister cells isolation with a starting cell 180 suspension of OD 600 0.3 used for biofilm growth instead of 0.1 as described in the 181 original protocols (8, 13). To assess the impact of the initial cell number used for 182 seeding biofilms on persister cells' appearance, we tested our protocol for SC5314 183 using cell suspensions of OD 600 0.1, 0.3 and 0.5 for seeding. Regardless of the initial 184 biomass, persister cells did not form in SC5314 biofilms grown either in RPMI or biofilms. Previously, Al-Dhaheri and Douglas showed that not all strains of 188 C. albicans can form persister cells (16). Particularly, in their hands, SC5314 biofilms 189 lost all viability after exposure to 30 μg/mL AMB. However, biofilms of another clinical 190 isolate, GDH2346, appeared to contain a small proportion (0.01%) of cells that 191 survived 100 μg/mL AMB treatment. These authors used a different in vitro model for 192 assessing persistence, as they grew biofilms on silicone disks that were transferred 193 to a new well filled with an antifungal solution. This prevented an escape of any cells 194 from the antifungal treatment. Thus, our modified protocol for treatment of biofilms 195 formed in 96-well or 24-well plates corroborated the results obtained by the Douglas 196 group for C. albicans strain SC5314 (16). 197
Since the clinical isolate GDH2346 could give rise to survivors (16), we could not 198 exclude that persisters could emerge in biofilms of different C. albicans isolates. 199
Additionally in 2010, LaFleur and colleagues isolated and described C. albicans 200 strains from patients with long-term oral infection, that gave yield to increased levels 201 of persisters (up to 8.9%) (23). These were called hip-mutants, by analogy with the 202 high persister strains previously described for bacteria (26, 27) . Although hip-mutants 203 were identified using a protocol that showed limitations in our hands, we 204
hypothesized that some C. albicans clinical isolates could generally be more prone to 205 form persisters than others (namely SC5314). To test this assumption, we tested 96 206 clinical isolates (Table S1 ) for their ability to form biofilms and the occurrence of 207 persister cells following AMB treatment. In a first round of experiments, biofilms were 208 treated with a 64 µg/mL AMB solution. Only 38 isolates (39.6%) displayed survivors 209 (notably, never exceeding a rate of 0.02%). According to the generally accepted handful of reports, sometimes contradictory, have been presented. In our study, we 238 explored standard protocols to obtain persisters, and showed that their proportion in 239 biofilms formed by different C. albicans strains has been overestimated. Our results 240
show that the detected "persister cells" were likely the result of survival of cells that 241 were not reached by the antifungal. Notably, Al-Dhaheri and Douglas (16) were able 242 to detect some persisters in biofilms of a clinical isolate, but the ratio they obtained 243 was much lower (0.01%) than the numbers published by other authors (8, 13) . 244
Although some of the tested clinical isolates of our study were occasionally able to 245 yield survivors after the treatment of biofilms with AMB, this phenomenon was rather 246 inconsistent, pointing either to the stochastic nature of persistence itself, or another 247 skew in the protocol while carrying out particular experiments. 248
At that point we cannot completely exclude the possibility of persistence in all existing 249 C. albicans strains, though with our protocol we managed to disprove their presence 250 for 91 analysed strains out of 98. grown in 1 mL of GHAUM medium in 24-well plates, and treated with 1 mL of AMB 364 solution (modified protocol from (13)). The values obtained from 5 biofilms were used 365 to draw the graph. 366 
Fig. 2. Schemes of the protocols (A) and levels of persisters (B) obtained
from biofilms grown using modified protocol from (13). Biofilms were grown in 1 mL of GHAUM medium in 24-well plates before application of either 1 mL of AMB solution (on the left) or 3 mL of AMB solution (on the right). Ratios of surviving cells are as follow: SC5314 -5.6*10 -4 %, CEC369 -2.6*10 -5 %, CEC4664 -9.4*10 -5 %.
Error bars: SD of 6 biological replicates generated from 2 independent experiments. Fig. 3 . Analysis of persister cell formation in 11 clinical isolates. Biofilms were grown in 1 mL of GHAUM medium in 24-well plates, and treated with 1 mL of AMB solution (modified protocol from (13)). The values obtained from 5 biofilms were used to draw the graph.
